Virginia Foxx
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Suspicious Timing Detected
2 flagsThese flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $ABBV | AbbVie Inc. Common Stock (ABBV) | $1K-$15K | $176.19 | $211.32 | +19.9% | Dec 6, 2024 |
| BUY | $AEP | American Electric Power Company, Inc. (AEP) | $1K-$15K | $95.85 | — | — | Dec 6, 2024 |
| BUY | $AMGN | Amgen Inc. - Common Stock (AMGN) | $1K-$15K | $272.58 | — | — | Dec 6, 2024 |
| BUY | $BMY | Bristol-Myers Squibb Company Common Stock (BMY) | $1K-$15K | — | — | — | Dec 6, 2024 |
| BUY | $DUK | Duke Energy Corporation (DUK) | $1K-$15K | $112.10 | — | — | Dec 6, 2024 |
| BUY | $EFC | Ellington Financial Inc. 7.00% Series D Cumulative Perpetual Redeemable Preferred Stock (EFC$D)(Corporate Securities) | $1K-$15K | — | — | — | Dec 30, 2024 |
| BUY | $JNJ | Johnson & Johnson Common Stock (JNJ) | $1K-$15K | $149.31 | — | — | Dec 6, 2024 |
| BUY | $PSA | Public Storage Common Stock (PSA) | $1K-$15K | $334.00 | — | — | Dec 6, 2024 |
| SELL | $T | AT&T Inc. Depositary Shares, each representing a 1/1,000th interest in a share of 5.000% Perpetual Preferred Stock, Series A (T$A)(Corporate Securities) | $50K-$100K | — | — | — | Dec 6, 2024 |
| PARTIAL SELL | $PBA | Pembina Pipeline Corp. Ordinary Shares (PBA) | $50K-$100K | $39.44 | $46.52 | +18.0% | Dec 6, 2024 |
Connected Legislative Activity
3 signalsThese bills and contracts share tickers or sectors with this filing's trades.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
HR1492 retroactively extends the Medicare price negotiation safe harbor for small-molecule drugs from 7 to 11 years, matching biologics. This shields billions in revenue for major pharma companies, particularly pure-play small-molecule firms like Vertex and large players with top-selling Part D drugs like Pfizer, Bristol-Myers Squibb, and Gilead. The bill is early-stage with 67 cosponsors and a Republican sponsor, giving it moderate momentum.
Growing and Preserving Innovation in America Act of 2025
HR1062 permanently locks in higher FDII and GILTI deductions for US multinationals, preventing a ~3.3 ppt effective tax rate increase on foreign IP income scheduled for 2026. This directly boosts after-tax net income for companies with large international revenue streams, including MSFT, AAPL, GOOGL, AMZN, NVDA, JNJ, PFE, KO, and PG. The bill is in early committee stage — structural impact is contingent on passage through the 119th Congress.
SMARTER Act
The SMARTER Act (HR1148) introduces direct bearish policy risk for the smart grid ecosystem. The bill removes federal support for smart grid cost recovery and requires states to consider banning ratepayer cost recovery entirely. Pure-play supplier Itron ($ITRI) faces the highest revenue exposure, with a 30-day decline of -5.44% and current price at $84.75 near its 52-week low of $78.53. Major utilities NextEra ($NEE), Duke ($DUK), and Sempra ($SRE) face regulatory uncertainty that could slow their multi-billion dollar grid modernization programs, though their diversified rate bases partially buffer the near-term impact. The bill is early-stage (referred to committee Feb 2025), but its legislative direction is unambiguous and negative for smart grid investment.
Other Filings by Virginia Foxx
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.